Seguir
Christopher Cleon Rowe
Christopher Cleon Rowe
University of Melbourne
E-mail confirmado em austin.org.au
Título
Citado por
Citado por
Ano
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines …
RA Sperling, PS Aisen, LA Beckett, DA Bennett, S Craft, AM Fagan, ...
Alzheimer's & dementia 7 (3), 280-292, 2011
82822011
NIA-AA research framework: toward a biological definition of Alzheimer's disease
CR Jack Jr, DA Bennett, K Blennow, MC Carrillo, B Dunn, SB Haeberlein, ...
Alzheimer's & dementia 14 (4), 535-562, 2018
79742018
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
B Dubois, HH Feldman, C Jacova, H Hampel, JL Molinuevo, K Blennow, ...
The Lancet Neurology 13 (6), 614-629, 2014
37332014
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
VL Villemagne, S Burnham, P Bourgeat, B Brown, KA Ellis, O Salvado, ...
The Lancet Neurology 12 (4), 357-367, 2013
23092013
Alzheimer's disease
CL Masters, R Bateman, K Blennow, CC Rowe, RA Sperling, ...
Nature reviews disease primers 1 (1), 1-18, 2015
18842015
Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria
B Dubois, H Hampel, HH Feldman, P Scheltens, P Aisen, S Andrieu, ...
Alzheimer's & Dementia 12 (3), 292-323, 2016
18802016
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ...
Jama 313 (19), 1924-1938, 2015
15872015
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
A Nakamura, N Kaneko, VL Villemagne, T Kato, J Doecke, V Doré, ...
Nature 554 (7691), 249-254, 2018
15762018
Imaging β-amyloid burden in aging and dementia
CC Rowe, S Ng, U Ackermann, SJ Gong, K Pike, G Savage, TF Cowie, ...
Neurology 68 (20), 1718-1725, 2007
12762007
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
CC Rowe, KA Ellis, M Rimajova, P Bourgeat, KE Pike, G Jones, J Fripp, ...
Neurobiology of aging 31 (8), 1275-1283, 2010
11292010
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
VL Villemagne, KE Pike, G Chételat, KA Ellis, RS Mulligan, P Bourgeat, ...
Annals of neurology 69 (1), 181-192, 2011
10192011
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
KE Pike, G Savage, VL Villemagne, S Ng, SA Moss, P Maruff, CA Mathis, ...
Brain 130 (11), 2837-2844, 2007
9682007
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
KA Johnson, S Minoshima, NI Bohnen, KJ Donohoe, NL Foster, ...
Alzheimer's & Dementia 9 (1), E1-E16, 2013
9502013
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of …
KA Ellis, AI Bush, D Darby, D De Fazio, J Foster, P Hudson, ...
International psychogeriatrics 21 (4), 672-687, 2009
9082009
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
WE Klunk, RA Koeppe, JC Price, TL Benzinger, MD Devous Sr, WJ Jagust, ...
Alzheimer's & dementia 11 (1), 1-15. e4, 2015
8092015
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
CC Rowe, U Ackerman, W Browne, R Mulligan, KL Pike, G O'Keefe, ...
The Lancet Neurology 7 (2), 129-135, 2008
7862008
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
B Dubois, N Villain, GB Frisoni, GD Rabinovici, M Sabbagh, S Cappa, ...
The Lancet Neurology 20 (6), 484-496, 2021
7072021
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
R Ossenkoppele, WJ Jansen, GD Rabinovici, DL Knol, WM van der Flier, ...
Jama 313 (19), 1939-1950, 2015
6462015
Tau imaging: early progress and future directions
VL Villemagne, MT Fodero-Tavoletti, CL Masters, CC Rowe
The Lancet Neurology 14 (1), 114-124, 2015
5652015
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study
O Sabri, MN Sabbagh, J Seibyl, H Barthel, H Akatsu, Y Ouchi, K Senda, ...
Alzheimer's & dementia 11 (8), 964-974, 2015
5152015
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20